WO2003000893A2 - Acides nucleiques codants pour des recepteurs couples a une proteine g - Google Patents

Acides nucleiques codants pour des recepteurs couples a une proteine g Download PDF

Info

Publication number
WO2003000893A2
WO2003000893A2 PCT/IB2002/002357 IB0202357W WO03000893A2 WO 2003000893 A2 WO2003000893 A2 WO 2003000893A2 IB 0202357 W IB0202357 W IB 0202357W WO 03000893 A2 WO03000893 A2 WO 03000893A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
gpcr
agent
polypeptide
gpcr gene
Prior art date
Application number
PCT/IB2002/002357
Other languages
English (en)
Other versions
WO2003000893A3 (fr
Inventor
Roger Moraga A. Martinez
Gunnar Thor Sigurdsson
Original Assignee
Decode Genetics Ehf.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf. filed Critical Decode Genetics Ehf.
Publication of WO2003000893A2 publication Critical patent/WO2003000893A2/fr
Publication of WO2003000893A3 publication Critical patent/WO2003000893A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Definitions

  • GPCRs G protein-coupled receptors
  • GPCRs are a superfamily of intrinsic transmembrane cell-surface receptors that mediate the transmission of extracellular signals into the cell to produce a cellular response. There are thought to be anywhere from 400 to over 1000 different members of this family. GPCRs are intrinsic membrane proteins, and operate by a common transduction mechanism. In their inactive state, the GPCRs bind to the G proteins. Upon activation, they stimulate guanine nucleotide exchange on the G proteins, resulting in the release of GDP and the binding of GTP. The G-protein then dissociates from the GPCR, and interacts with the adenylate cyclases, which catalyze the conversion of ATP into cAMP. The cAMP then acts as a second messenger.
  • the G proteins can cause intracellular coupling of the GPCRs with various intracellular enzymes, ion channels and transporters.
  • GPCRs and perforce, G proteins are involved in an enormous range of biological processes, and have been found to regulate such processes as hydrolysis
  • the signal can be endogenous or exogenous or, in the case of rhodopsin receptors, the stimulus can be light.
  • Many drugs bind to a GPCR and either produce a response or block the actions of the normal signal.
  • the GPCR superfamily includes the cannabinoid and opioid receptors, chemokine, histamine, angiotensin, neurotensin, vasopressin, calcitonin, dopamine, glutamate and bombesin receptors, taste and odorant receptors, and many others.
  • the present invention relates to human G protein-coupled receptor (GPCR) genes, particularly nucleic acids comprising GPCR genes, and the amino acids encoded by such nucleic acids.
  • GPCR human G protein-coupled receptor
  • Sub-family information on the sequences is shown in Table El. For each sequence, the following information is provided: the University of California at Santa Cruz contig designation from which the sequence was analyzed (e.g., "ctgl4797"), the name (e.g., "MOOSE00162”), and the subfamily to which the sequence appears to belong. The assignments were made on the basis of the best E- value with which the sequence aligned. Sequences listed as "Class A Orphan" are those that have been characterized, and are known to bind GPCR-proteins.
  • the isolated nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers), as shown in Tables I and ⁇ , and the complements thereof.
  • the invention further relates to a nucleic acid molecule which hybridizes under high stringency conditions to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers), as shown in Tables I and II, and the complements thereof.
  • the invention additionally relates to isolated nucleic acid molecules (e.g., cDNA molecules) encoding a GPCR polypeptide (e.g., encoding a polypeptide selected from the group consisting of SEQ ID NOs: 1-124 (even numbers), as shown in Tables I and II).
  • isolated nucleic acid molecules e.g., cDNA molecules
  • GPCR polypeptide e.g., encoding a polypeptide selected from the group consisting of SEQ ID NOs: 1-124 (even numbers), as shown in Tables I and II.
  • the invention further provides a method for assaying a sample for the presence of a nucleic acid molecule comprising all or a portion of a GPCR in a sample, comprising contacting said sample with a second nucleic acid molecule comprising a nucleotide sequence encoding a GPCR polypeptide (e.g., one of SEQ ID NOs: 1-124 (odd numbers), as shown in Tables I and II, or the complement of one of SEQ ID NOs: 1-124 (odd numbers); a nucleotide sequence encoding one of SEQ ID NOs: 1-124 (even numbers), as shown in Tables I and TT), or a fragment or derivative thereof, under conditions appropriate for selective hybridization.
  • a GPCR polypeptide e.g., one of SEQ ID NOs: 1-124 (odd numbers), as shown in Tables I and II, or the complement of one of SEQ ID NOs: 1-124 (odd numbers)
  • the invention additionally provides a method for assaying a sample for the level of expression of a GPCR polypeptide, or fragment or derivative thereof, comprising detecting (directly or indirectly) the level of expression of the GPCR polypeptide, fragment or derivative thereof.
  • the invention also relates to a vector comprising an isolated nucleic acid molecule of the invention operatively linked to a regulatory sequence, as well as to a recombinant host cell comprising the vector.
  • the invention also provides a method for preparing a polypeptide encoded by an isolated nucleic acid molecule described herein (a GPCR polypeptide), comprising culturing a recombinant host cell of the invention under conditions suitable for expression of said nucleic acid molecule.
  • the invention further provides an isolated polypeptide encoded by isolated nucleic acid molecules of the invention (e.g., GPCR polypeptide), as well as fragments or derivatives thereof.
  • the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-124 (even numbers), as shown in Tables I and II.
  • the invention also relates to an isolated polypeptide comprising an amino acid sequence which is greater than about 90 percent identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-124 (even numbers), preferably about 95, 96, 97, 98 and 99 percent identical.
  • the invention also relates to an antibody, or an antigen-binding fragment thereof, which selectively binds to a polypeptide of the invention, as well as to a method for assaying the presence of a polypeptide encoded by an isolated nucleic acid molecule of the invention in a sample, comprising contacting said sample with an antibody which specifically binds to the encoded polypeptide.
  • the invention further relates to methods of diagnosing a predisposition to a condition mediated by GPCRs.
  • the methods of diagnosing such a predisposition in an individual include detecting the presence of a mutation in GPCR, as well as detecting alterations in expression of a GPCR polypeptide, such as the presence of different splicing variants of GPCR polypeptides.
  • the alterations in expression can be quantitative, qualitative, or both quantitative and qualitative.
  • the invention additionally relates to an assay for identifying agents that alter (e.g., enhance or inhibit) the activity or expression of one or more GPCR polypeptides.
  • a cell, cellular fraction, or solution containing a GPCR polypeptide or a fragment or derivative thereof can be contacted with an agent to be tested, and the level of GPCR polypeptide expression or activity can be assessed.
  • the activity or expression of more than one GPCR polypeptides can be assessed concurrently (e.g., the cell, cellular fraction, or solution can contain more than one type of GPCR polypeptide, such as different splicing variants, and the levels of the different polypeptides or splicing variants can be assessed).
  • the invention in another embodiment, relates to assays to identify polypeptides that interact with one or more GPCR polypeptides.
  • a first vector is used which includes a nucleic acid encoding a DNA binding domain and also an GPCR polypeptide, splicing variant, or fragment or derivative thereof
  • a second vector is used which includes a nucleic acid encoding a transcription activation domain and also a nucleic acid encoding a polypeptide which potentially may interact with the GPCR polypeptide, splicing variant, or fragment or derivative thereof (e.g., a GPCR polypeptide binding agent or receptor).
  • Incubation of yeast containing both the first vector and the second vector under appropriate conditions allows identification of polypeptides which interact with the GPCR polypeptide or fragment or derivative thereof, and thus can be agents which alter the activity of expression of an GPCR polypeptide.
  • Agents that enhance or inhibit GPCR polypeptide expression or activity are also included in the current invention, as are methods of altering (enhancing or inhibiting) GPCR polypeptide expression or activity by contacting a cell containing GPCR and/or polypeptide, or by contacting the GPCR polypeptide, with an agent that enhances or inhibits expression or activity of GPCR or polypeptide.
  • the invention pertains to pharmaceutical compositions comprising the nucleic acids of the invention, the polypeptides of the invention, and/or the agents that alter activity of GPCR polypeptide.
  • the invention further pertains to methods of treating conditions mediated by GPCRs, by administering GPCR therapeutic agents, such as nucleic acids of the invention, polypeptides of the invention, the agents that alter activity of GPCR polypeptide, or compositions comprising the nucleic acids, polypeptides, and/or the agents that alter activity of GPCR polypeptide.
  • the present invention relates to nucleic acids comprising G protein-coupled receptors ("GPCRs”), and the GPCR amino acids encoded by those nucleic acids.
  • GPCRs G protein-coupled receptors
  • the GPCR superfamily includes the receptors for many important signaling pathways, including, but not limited to, hormone receptors, growth factors, viral receptors, neuroreceptors, etc., such as acetylcholine, adrenocorticotropin (ACTH), adenosine, ⁇ -adrenergic receptors, ⁇ -adrenergic receptors, angiotensin, bombesin, bradykinin, C5a, calcitonin, cAMP, cannabinoid, C-C chemokine, cholecystokinin/gastrin (CCK/gastrin), cytomegalovirus, dopamine, endothelial differentiation gene-1, endothelin, formyl peptide, glutamate (metabo
  • These receptors are involved in the treatment of infections and various diseases and conditions, including, but not limited to, bacterial, fungal, protozoan and viral infections, particularly infections caused by HTV-1 or HJV-2; cancers; diabetes; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy (benign prostatic hyperplasia); chronic renal failure; renal disease; impaired glucose tolerance; seizure disorder; depression; anxiety; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder; anxiety neurosis; dysthymic disorder; behavior disorder; mood disorder; shizophrenia; psychosexual dysfunction; sex disorder; sexual disorder; disturbed biological and circadian rhythms; feeding disorders, such as anorexia, bulimia, cachexia, and obesity; Cushing's syndrome/disease; basophil
  • HMMs Hidden Markov Models
  • sequences were subdivided in several families so that the similarity inside of a group of them was over 50%. Given this approach, there are several points of overlap between different families when analyzing a sequence, so the discrimination must be done after the search is completed.
  • Several resources that include expert-supervised classifications are used to select the best groups of sequences, e.g., the GPCR database (Horn et al, Nucleic Acids Res. 26(l):275-9, 1998), PKR (Smith et al, Trends Biochem. Sci. 22(1 1):444- 6, 1997), NuclearRdb (Horn et al, Nucleic Acids Res.
  • DiAlign works based on segment-to-segment comparisons instead of arbitrary thresholds for gap opening and extension, which makes it ideally suited for building models that represent an entire, full-length sequence, since the alignments built this way have more match states that would be assigned as insertion states when using other alignment algorithms.
  • the models were built using the standard HMMer package. To search for new genes, a genome-wide scan was done on the University of California at Santa Cruz sequences, using the Gene Wise algorithm. It translates the genomic sequence on the fly to proteins and can therefore maintain a reading frame through insertions and deletions. The algorithm also rewards gaps in the genomic sequence relative to the model if they are encapsulated within introns, like splice structure.
  • a classification was obtained in which the sequences are grouped by length and similarity. Each one of these groups was then used to build a HMM profile representing this group of sequences.
  • This approach aims to have models that can represent the full length of the encoded proteins for a whole range of proteins, without being too specific for any one of them or being too general, as would be a HMM built for large groups of sequences.
  • This classification was based either on existing expert-supervised classifications, or by retrieval of sequences and classification based on pairwise alignment distances. These models were then searched against the October 2000 Fixed Release
  • a span of one LOD drop around the marker was also given.
  • a computer program takes each LOD peak and links it to the consensus through the markerhit in the database.
  • the database is then queried for all HMM genes within the span of one LOD drop or a minimum of 15 Mb in each direction from the marker.
  • the output is the name of the peak marker and its distance to the HMM gene.
  • the invention pertains to isolated nucleic acid molecules comprising human GPCR genes.
  • GPCR refers to an isolated nucleic acid molecule selected from the group shown in Tables I and II, and consisting of SEQ ID NOs: 1-124 (odd numbers), and also to a portion or fragment of the isolated nucleic acid molecule (e.g., cDNA or the gene) that encodes GPCR polypeptide (e.g., a polypeptide selected from the group shown in Tables I and II, and consisting of SEQ ID NOs: 1-124 (even numbers)).
  • the isolated nucleic acid molecule comprises a nucleic acid molecule selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers) or the complement of such a nucleic acid molecule.
  • the isolated nucleic acid molecules of the present invention can be RNA, for example, mRNA, or DNA, such as cDNA and genomic DNA.
  • DNA molecules can be double-stranded or single-stranded; single stranded RNA or DNA can be the coding, or sense, strand or the non-coding, or antisense, strand.
  • the nucleic acid molecule can include all or a portion of the coding sequence of the gene and can further comprise additional non-coding sequences such as introns and non-coding 3' and 5' sequences (including regulatory sequences, for example).
  • the nucleic acid molecule can be fused to a marker sequence, for example, a sequence that encodes a polypeptide to assist in isolation or purification of the polypeptide.
  • Such sequences include, but are not limited to, those that encode a glutathione-S- transferase (GST) fusion protein and those that encode a hemagglutinin A (HA) polypeptide marker from influenza.
  • an "isolated" nucleic acid molecule is one that is separated from nucleic acids that normally flank the gene or nucleotide sequence (as in genomic sequences) and/or has been completely or partially purified from other transcribed sequences (e.g., as in an RNA library).
  • an isolated nucleic acid of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.
  • the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix.
  • an isolated nucleic acid molecule comprises at least about 50, 80 or 90% (on a molar basis) of all macromolecular species present.
  • genomic DNA the term “isolated” also can refer to nucleic acid molecules that are separated from the chromosome with which the genomic DNA is naturally associated.
  • the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotides which flank the nucleic acid molecule in the genomic DNA of the cell from which the nucleic acid molecule is derived.
  • the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.
  • recombinant DNA contained in a vector is included in the definition of "isolated" as used herein.
  • isolated nucleic acid molecules include recombinant DNA molecules in heterologous host cells, as well as partially or substantially purified DNA molecules in solution.
  • isolated nucleic acid molecules also encompass in vivo and in vitro RNA transcripts of the DNA molecules of the present invention.
  • An isolated nucleic acid molecule or nucleotide sequence can include a nucleic acid molecule or nucleotide sequence that is synthesized chemically or by recombinant means. Therefore, recombinant DNA contained in a vector is included in the definition of "isolated” as used herein.
  • isolated nucleotide sequences include recombinant DNA molecules in heterologous organisms, as well as partially or substantially purified DNA molecules in solution. In vivo and in vitro RNA transcripts of the DNA molecules of the present invention are also encompassed by "isolated" nucleotide sequences.
  • Such isolated nucleotide sequences are useful in the manufacture of the encoded polypeptide, as probes for isolating homologous sequences (e.g., from other mammalian species), for gene mapping (e.g., by in situ hybridization with chromosomes), or for detecting expression of the gene in tissue (e.g., human tissue), such as by Northern blot analysis.
  • homologous sequences e.g., from other mammalian species
  • gene mapping e.g., by in situ hybridization with chromosomes
  • tissue e.g., human tissue
  • the present invention also pertains to nucleic acid molecules which are not necessarily found in nature but which encode a GPCR polypeptide (e.g., a polypeptide having an amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:l-124 (even numbers)), or another splicing variant of a GPCR polypeptide or polymo ⁇ hic variant thereof.
  • a GPCR polypeptide e.g., a polypeptide having an amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:l-124 (even numbers)
  • another splicing variant of a GPCR polypeptide or polymo ⁇ hic variant thereof e.g., a polypeptide having an amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:l-124 (even numbers)
  • DNA molecules which comprise a sequence that is different from the naturally-occurring nucleotide sequence but which, due to the degeneracy of the genetic code, encode a GPCR polypeptide of the present invention are also the subject of this invention.
  • the invention also encompasses nucleotide sequences encoding portions (fragments), or encoding variant polypeptides such as analogues or derivatives of a GPCR polypeptide.
  • variants can be naturally-occurring, such as in the case of allelic variation or single nucleotide polymorphisms, or non- naturally-occurring, such as those induced by various mutagens and mutagenic processes.
  • nucleotide sequences are fragments that comprise one or more polymorphic microsatellite markers. In another preferred embodiment, the nucleotide sequences are fragments that comprise one or more single nucleotide polymorphisms in a GPCR gene.
  • nucleic acid molecules of the invention can include, for example, labeling, methylation, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates), charged linkages (e.g., phosphorothioates, phosphorodithioates), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids). Also included are synthetic molecules that mimic nucleic acid molecules in the ability to bind to designated sequences via hydrogen bonding and other chemical interactions.
  • uncharged linkages e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates
  • charged linkages e.g., phosphorothioates, phosphorodithioates
  • pendent moieties
  • Such molecules include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.
  • the invention also pertains to nucleic acid molecules that hybridize under high stringency hybridization conditions, such as for selective hybridization, to a nucleotide sequence described herein (e.g., nucleic acid molecules which specifically hybridize to a nucleotide sequence encoding polypeptides described herein, and, optionally, have an activity of the polypeptide).
  • the invention includes variants described herein which hybridize under high stringency hybridization conditions (e.g., for selective hybridization) to a nucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers).
  • the invention includes variants described herein which hybridize under high stringency hybridization conditions
  • nucleic acid molecules can be detected and/or isolated by specific hybridization (e.g., under high stringency conditions).
  • Specific hybridization refers to the ability of a first nucleic acid to hybridize to a second nucleic acid in a manner such that the first nucleic acid does not hybridize to any nucleic acid other than to the second nucleic acid (e.g., when the first nucleic acid has a higher similarity to the second nucleic acid than to any other nucleic acid in a sample wherein the hybridization is to be performed).
  • “Stringency conditions” for hybridization is a term of art which refers to the incubation and wash conditions, e.g., conditions of temperature and buffer concentration, which permit hybridization of a particular nucleic acid to a second nucleic acid; the first nucleic acid may be perfectly (i.e., 100%) complementary to the second, or the first and second may share some degree of complementarity which is less than perfect (e.g., 70%, 75%, 85%>, 90%, 95%). For example, certain high stringency conditions can be used which distinguish perfectly complementary nucleic acids from those of less complementarity.
  • hybridization conditions from a level of stringency at which no hybridization occurs to a level at which hybridization is first observed, conditions which will allow a given sequence to hybridize (e.g., selectively) with the most similar sequences in the sample can be determined.
  • washing is the step in which conditions are usually set so as to determine a minimum level of complementarity of the hybrids. Generally, starting from the lowest temperature at which only homologous hybridization occurs, each °C by which the final wash temperature is reduced (holding SSC concentration constant) allows an increase by 1% in the maximum extent of mismatching among the sequences that hybridize.
  • the washing temperature can be determined empirically for high, moderate or low stringency, depending on the level of mismatch sought.
  • a low stringency wash can comprise washing in a solution containing 0.2X SSC/0.1% SDS for 10 minutes at room temperature;
  • a moderate stringency wash can comprise washing in a prewarmed solution (42°C) solution containing 0.2X SSC/0.1% SDS for 15 minutes at 42°C;
  • a high stringency wash can comprise washing in prewarmed (68°C) solution containing 0.1X SSC/0.1%SDS for 15 minutes at 68°C.
  • washes can be performed repeatedly or sequentially to obtain a desired result as known in the art.
  • Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleic acid molecule and the primer or probe used.
  • the length of a sequence aligned for comparison pu ⁇ oses is at least 30%, preferably at least 40%, more preferably at least 60%, and even more preferably at least 70%, 80%, 90% or 95% of the length of the reference sequence.
  • the default parameters of the respective programs e.g., NBLAST
  • Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller C_3/OS 4(1): 11-17, 1998. Such an algorithm is inco ⁇ orated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package (ACCELRYS, Cambridge, UK).
  • a PAM120 weight residue table When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art and include ADVANCE and ADAM as described in Torellis and Robotti, Comput. Appl. Biosci. 10:3-5, 1994; and FASTA described in Pearson and Lipman Proc. Natl. Acad. Sci. USA 85:2444-8, 1988.
  • the percent identity between two amino acid sequences can be accomplished using the GAP program in the GCG software package using either a BLOSUM63 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4.
  • the percent identity between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package, using a gap weight of 50 and a length weight of 3.
  • the present invention also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ JD NOs: 1 - 124 (odd numbers), or the complement of such a sequence, and also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleotide sequence encoding an amino acid sequence selected SEQ ID NOs: 1-124 (even numbers), or polymo ⁇ hic variant thereof.
  • the nucleic acid fragments of the invention are at least about 15, preferably at least about 18, 20, 23 or 25 nucleotides, and can be 30, 40, 50, 100, 200 or more nucleotides in length. Longer fragments, for example, 30 or more nucleotides in length, which encode antigenic polypeptides described herein are particularly useful, such as for the generation of antibodies as described below.
  • nucleic acid fragments of the invention are used as probes or primers in assays such as those described herein.
  • Probes or “primers” are oligonucleotides that hybridize in a base-specific manner to a complementary strand of nucleic acid molecules.
  • probes and primers include polypeptide nucleic acids, as described in Nielsen et al, Science 254: 1497-1500, (1991).
  • a probe or primer comprises a region of nucleotide sequence that hybridizes to at least about 15, typically about 20-25, and more typically about 40, 50 or 75, consecutive nucleotides of a nucleic acid molecule comprising a contiguous nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers), or the complement of such a sequence, or a sequence encoding an amino acid sequence selected from SEQ ID NOs: 1-124 (even numbers), or polymo ⁇ hic variant thereof.
  • a probe or primer comprises 100 or fewer nucleotides, preferably from 6 to 50 nucleotides, preferably from 12 to 30 nucleotides.
  • the probe or primer is at least 70%) identical to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence, preferably at least 80% identical, more preferably at least 90% identical, even more preferably at least 95% identical, or even capable of selectively hybridizing to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence.
  • the probe or primer further comprises a label, e.g., radioisotope, fluorescent compound, enzyme, or enzyme co-factor.
  • nucleic acid molecules of the invention such as those described above can be identified and isolated using standard molecular biology techniques and the sequence information provided herein.
  • nucleic acid molecules can be amplified and isolated by the polymerase chain reaction using synthetic oligonucleotide primers designed based on one or more of the sequences selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers), or the complement of such a sequence, or designed based on nucleotides based on sequences encoding one or more of the amino acid sequences provided herein. See generally PCR Technology: Principles and Applications for DNA Amplification (ed. H.A. Erlich,
  • the nucleic acid molecules can be amplified using cDNA, mRNA or genomic DNA as a template, cloned into an appropriate vector and characterized by DNA sequence analysis.
  • Other suitable amplification methods include the ligase chain reaction (LCR)
  • ssRNA single stranded RNA
  • dsDNA double stranded DNA
  • the amplified DNA can be radiolabelled and used as a probe for screening a cDNA library derived from human cells, mRNA in zap express, ZIPLOX or other suitable vector.
  • Corresponding clones can be isolated, DNA can obtained following in vivo excision, and the cloned insert can be sequenced in either or both orientations by art recognized methods to identify the correct reading frame encoding a polypeptide of the appropriate molecular weight.
  • the direct analysis of the nucleotide sequence of nucleic acid molecules of the present invention can be accomplished using well-known methods that are commercially available.
  • polypeptide and the DNA encoding the polypeptide can be isolated, sequenced and further characterized.
  • Antisense nucleic acid molecules of the invention can be designed using the nucleotide sequences of one or more of SEQ ID NOs: 1-124 (odd numbers) and or the complement of one or more of SEQ ID NOs: 1-124 (odd numbers), and/or a portion of one or more of SEQ ID NOs: 1-124 (odd numbers), or the complement of one or more of SEQ ID NOs:l-124 (odd numbers) and/or a sequence encoding the amino acid sequences of one or more of SEQ ID NOs: 1-124 (even numbers), or encoding a portion of one or more of SEQ ID NOs: 1-124 (even numbers), and constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
  • an antisense nucleic acid molecule e.g., an antisense oligonucleotide
  • an antisense nucleic acid molecule can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.
  • the antisense nucleic acid molecule can be produced biologically using an expression vector into which a nucleic acid molecule has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid molecule will be of an antisense orientation to a target nucleic acid of interest).
  • the isolated nucleic acid sequences of the invention can be used as molecular weight markers on Southern gels, and as chromosome markers which are labeled to map related gene positions.
  • the nucleic acid sequences can also be used to compare with endogenous DNA sequences in patients to identify one or more of the disorders described above, and as probes, such as to hybridize and discover related DNA sequences or to subtract out known sequences from a sample.
  • the nucleic acid sequences can further be used to derive primers for genetic finge ⁇ rinting, to raise anti-polypeptide antibodies using DNA immunization techniques, and as an antigen to raise anti-DNA antibodies or elicit immune responses.
  • nucleotide sequences identified herein can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Additionally, the nucleotide sequences of the invention can be used to identify and express recombinant polypeptides for analysis, characterization or therapeutic use, or as markers for tissues in which the corresponding polypeptide is expressed, either constitutively, during tissue differentiation, or in diseased states.
  • nucleic acid sequences can additionally be used as reagents in the screening and/or diagnostic assays described herein, and can also be included as components of kits (e.g., reagent kits) for use in the screening and/or diagnostic assays described herein.
  • kits e.g., reagent kits
  • nucleic acid constructs containing a nucleic acid molecule selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers) and the complements thereof (or a portion thereof).
  • nucleic acid constructs containing a nucleic acid molecule encoding an amino acid sequence of SEQ ID NOs: 1-124 (even numbers) or polymo ⁇ hic variant thereof.
  • the constructs comprise a vector (e.g., an expression vector) into which a sequence of the invention has been inserted in a sense or antisense orientation.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • vector refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
  • viral vector Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • certain vectors, expression vectors are capable of directing the expression of genes to which they are operably linked.
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses) that serve equivalent functions.
  • viral vectors e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses
  • Preferred recombinant expression vectors of the invention comprise a nucleic acid molecule of the invention in a form suitable for expression of the nucleic acid molecule in a host cell.
  • the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed.
  • "operably linked” or "operatively linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
  • regulatory sequence is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, “Gene Expression Technology", Methods in Enzymology
  • Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed and the level of expression of polypeptide desired.
  • the expression vectors of the invention can be introduced into host cells to thereby produce polypeptides, including fusion polypeptides, encoded by nucleic acid molecules as described herein.
  • the recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic or eukaryotic cells, e.g., bacterial cells such as E. coli, insect cells (using baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, supra.
  • the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
  • Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced.
  • host cell and
  • progeny refers not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
  • a host cell can be any prokaryotic or eukaryotic cell.
  • a nucleic acid molecule of the invention can be expressed in bacterial cells (e.g., E. coli), insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells).
  • bacterial cells e.g., E. coli
  • insect cells e.g., insect cells
  • yeast or mammalian cells such as Chinese hamster ovary cells (CHO) or COS cells.
  • Other suitable host cells are known to those skilled in the art.
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and “transfection” are intended to refer to a variety of art- recognized techniques for introducing a foreign nucleic acid molecule (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation,
  • a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
  • selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate.
  • Nucleic acid molecules encoding a selectable marker can be introduced into a host cell on the same vector as the nucleic acid molecule of the invention or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid molecule can be identified by drug selection (e.g., cells that have inco ⁇ orated the selectable marker gene will survive, while the other cells die).
  • a host cell of the invention such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a polypeptide of the invention.
  • the invention further provides methods for producing a polypeptide using the host cells of the invention.
  • the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced.
  • the method further comprises isolating the polypeptide from the medium or the host cell.
  • a host cell of the invention can also be used to produce nonhuman transgenic animals.
  • a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a nucleic acid molecule of the invention has been introduced (e.g., an exogenous GPCR gene, or an exogenous nucleic acid encoding a GPCR polypeptide).
  • a nucleic acid molecule of the invention e.g., an exogenous GPCR gene, or an exogenous nucleic acid encoding a GPCR polypeptide.
  • Such host cells can then be used to create non-human transgenic animals in which exogenous nucleotide sequences have been introduced into the genome or homologous recombinant animals in which endogenous nucleotide sequences have been altered.
  • transgenic animal is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal include a transgene.
  • rodent such as a rat or mouse
  • transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens and amphibians.
  • a transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.
  • an "homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
  • Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al (1997) Nature 385:810-813 and PCT Publication Nos. WO 97/07668 and WO 97/07669.
  • GPCR polypeptides and fragments and variants thereof, as well as polypeptides encoded by nucleotide sequences described herein (e.g., other splicing variants).
  • polypeptide refers to a polymer of amino acids, and not to a specific length; thus, peptides, oligopeptides and proteins are included within the definition of a polypeptide. As used herein, a polypeptide is said to be "isolated" or
  • purified when it is substantially free of cellular material when it is isolated from recombinant and non-recombinant cells, or free of chemical precursors or other chemicals when it is chemically synthesized.
  • a polypeptide can be joined to another polypeptide with which it is not normally associated in a cell (e.g., in a "fusion protein") and still be “isolated” or “purified.”
  • polypeptides of the invention can be purified to homogeneity. It is understood, however, that preparations in which the polypeptide is not purified to homogeneity are useful. The critical feature is that the preparation allows for the desired function of the polypeptide, even in the presence of considerable amounts of other components. Thus, the invention encompasses various degrees of purity.
  • the language "substantially free of cellular material” includes preparations of the polypeptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins.
  • a polypeptide When a polypeptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20%, less than about 10%, or less than about 5% of the volume of the polypeptide preparation.
  • culture medium represents less than about 20%, less than about 10%, or less than about 5% of the volume of the polypeptide preparation.
  • substantially free of chemical precursors or other chemicals includes preparations of the polypeptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language
  • substantially free of chemical precursors or other chemicals includes preparations of the polypeptide having less than about 30% ⁇ (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10%) chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.
  • a polypeptide of the invention comprises an amino acid sequence encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers), or the complement of such a nucleic acid, or portions thereof, e.g., SEQ ID NO: 1-124 (even numbers), or a portion or polymo ⁇ hic variant thereof.
  • the polypeptides of the invention also encompass fragment and sequence variants.
  • Variants include a substantially homologous polypeptide encoded by the same genetic locus in an organism, i.e., an allelic variant, as well as other splicing variants.
  • Variants also encompass polypeptides derived from other genetic loci in an organism, but having substantial homology to a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-124 (odd numbers), or a complement of such a sequence, or portions thereof, or having substantial homology to a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of nucleotide sequences encoding SEQ ID NOs:l-124 (even numbers), or polymo ⁇ hic variants thereof.
  • Variants also include polypeptides substantially homologous or identical to these polypeptides but derived from another organism, i.e., an ortholog. Variants also include polypeptides that are substantially homologous or identical to these polypeptides that are produced by chemical synthesis. Variants also include polypeptides that are substantially homologous or identical to these polypeptides mat are produced by recombinant methods. As used herein, two polypeptides (or a region of the polypeptides) are substantially homologous or identical when the amino acid sequences are at least about 45-55%), typically at least about 70-75%, more typically at least about 80- 85%, and most typically greater than about 90% or more homologous or identical.
  • a substantially homologous amino acid sequence will be encoded by a nucleic acid molecule hybridizing to one or more of SEQ ID NOs: 1-124 (odd numbers), or portion thereof, under stringent conditions as more particularly described above, or will be encoded by a nucleic acid molecule hybridizing to a nucleic acid sequence encoding one of SEQ ID NOs: 1-124 (even numbers), a portion thereof or polymo ⁇ hic variant thereof, under stringent conditions as more particularly described thereof.
  • amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid "identity”.
  • the percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., percent homology equals the number of identical positions/total number of positions times 100).
  • the invention also encompasses polypeptides having a lower degree of identity but having sufficient similarity so as to perform one or more of the same functions performed by a polypeptide encoded by a nucleic acid molecule of the invention. Similarity is determined by conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Conservative substitutions are likely to be phenotypically silent.
  • conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and He; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gin, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe and Tyr.
  • Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al, Science 247:1306-1310 (1990).
  • variant polypeptide can differ in amino acid sequence by one or more substitutions, deletions, insertions, inversions, fusions, and truncations or a combination of any of these. Further, variant polypeptides can be fully functional or can lack function in one or more activities. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non- critical regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.
  • Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.
  • Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis
  • Fragments can be derived from a polypeptide encoded by a nucleic acid molecule comprising one of SEQ ID NOs:l-124 (odd numbers), or a complement of such a nucleic acid (e.g., SEQ ID NOs:l-124 (even numbers), or other variants).
  • the invention also encompasses fragments of the variants of the polypeptides described herein.
  • a fragment comprises at least 6 contiguous amino acids.
  • Useful fragments include those that retain one or more of the biological activities of the polypeptide as well as fragments that can be used as an immunogen to generate polypeptide-specific antibodies.
  • Biologically active fragments peptides which are, for example, 6, 9, 12, 15,
  • 16, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length can comprise a domain, segment, or motif that has been identified by analysis of the polypeptide sequence using well-known methods, e.g., signal peptides, extracellular domains, one or more transmembrane segments or loops, ligand binding regions, zinc finger domains, DNA binding domains, acylation sites, glycosylation sites, or phosphorylation sites.
  • Fragments can be discrete (not fused to other amino acids or polypeptides) or can be within a larger polypeptide. Further, several fragments can be comprised within a single larger polypeptide. In one embodiment a fragment designed for expression in a host can have heterologous pre- and pro-polypeptide regions fused to the amino terminus of the polypeptide fragment and an additional region fused to the carboxyl terminus of the fragment.
  • the invention thus provides chimeric or fusion polypeptides.
  • These comprise a polypeptide of the invention operatively linked to a heterologous protein or polypeptide having an amino acid sequence not substantially homologous to the polypeptide.
  • “Operatively linked” indicates that the polypeptide and the heterologous protein are fused in-frame.
  • the heterologous protein can be fused to the N-terminus or C-terminus of the polypeptide.
  • the fusion polypeptide does not affect function of the polypeptide per se.
  • the fusion polypeptide can be a GST-fusion polypeptide in which the polypeptide sequences are fused to the C-terminus of the GST sequences.
  • fusion polypeptides include, but are not limited to, enzymatic fusion polypeptides, for example ⁇ -galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions and Ig fusions.
  • enzymatic fusion polypeptides for example ⁇ -galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions and Ig fusions.
  • Such fusion polypeptides particularly poly-His fusions, can facilitate the purification of recombinant polypeptide.
  • expression and/or secretion of a polypeptide can be increased using a heterologous signal sequence. Therefore, in another embodiment, the fusion polypeptide contains a heterologous signal sequence at its N-terminus.
  • EP-A-O 464 533 discloses fusion proteins comprising various portions of immunoglobulin constant regions.
  • the Fc is useful in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262).
  • human proteins have been fused with Fc portions for the pu ⁇ ose of high-throughput screening assays to identify antagonists. Bennett et al, J. Mol. Recog. 8:52-58 (1995) and Johanson et al, J. Biol. Chem. 270:16:9459- 9471 (1995).
  • this invention also encompasses soluble fusion polypeptides containing a polypeptide of the invention and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE).
  • a chimeric or fusion polypeptide can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques.
  • the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
  • PCR amplification of nucleic acid fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive nucleic acid fragments which can subsequently be annealed and re-amplified to generate a chimeric nucleic acid sequence (see Ausubel et al, Current Protocols in Molecular Biology, 1992).
  • fusion moiety e.g., a GST protein
  • a nucleic acid molecule encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide.
  • the isolated polypeptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods.
  • the polypeptide is produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the polypeptide is cloned into an expression vector, the expression vector introduced into a host cell and the polypeptide expressed in the host cell. The polypeptide can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques.
  • polypeptides of the present invention can be used as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using art-recognized methods.
  • the polypeptides of the present invention can be used to raise antibodies or to elicit an immune response.
  • the polypeptides can also be used as a reagent, e.g., a labeled reagent, in assays to quantitatively determine levels of the polypeptide or a molecule to which it binds (e.g., a ligand) in biological fluids.
  • the polypeptides can also be used as markers for cells or tissues in which the corresponding polypeptide is preferentially expressed, either constitutively, during tissue differentiation, or in a disease state.
  • the polypeptides can be used to isolate a corresponding binding agent, e.g., ligand, such as, for example, in an interaction trap assay, and to screen for peptide or small molecule antagonists or agonists of the binding interaction.
  • Polyclonal and/or monoclonal antibodies that specifically bind one form of the gene product but not to the other form of the gene product are also provided.
  • Antibodies are also provided which bind a portion of either the variant or the reference gene product that contains the polymo ⁇ hic site or sites.
  • the invention provides antibodies to the polypeptides and polypeptide fragments of the invention, e.g., having an amino acid sequence of one of SEQ ID NOs: 1-124 (even numbers) or a portion thereof, or having an amino acid sequence encoded by a nucleic acid molecule comprising all or a portion of SEQ JJD NOs: 1-124 (odd numbers), or a complement or another variant or portion thereof.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds an antigen.
  • a molecule that specifically binds to a polypeptide of the invention is a molecule that binds to that polypeptide or a fragment thereof, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide.
  • immunologically active portions of immunoglobulin molecules include F(ab) and F(ab') 2 fragments which can be generated by treating the antibody with an enzyme such as pepsin.
  • the invention provides polyclonal and monoclonal antibodies that bind to a polypeptide of the invention.
  • a monoclonal antibody composition thus typically displays a single binding affinity for a particular polypeptide of the invention with which it immunoreacts.
  • Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a desired immunogen, e.g., polypeptide of the invention or fragment thereof.
  • a desired immunogen e.g., polypeptide of the invention or fragment thereof.
  • the antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide.
  • ELISA enzyme linked immunosorbent assay
  • the antibody molecules directed against the polypeptide can be isolated from the mammal (e.g., from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction.
  • antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) Immunol. Today 4:72), The EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques.
  • the technology for producing hybridomas is well known (see generally Current Protocols in Immunology (1994) Coligan et al.
  • an immortal cell line typically a myeloma
  • lymphocytes typically splenocytes
  • the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a polypeptide of the invention.
  • a monoclonal antibody to a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide to thereby isolate immunoglobulin library members that bind the polypeptide.
  • Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01 ; and the Stratagene Swr/ZAPTM
  • recombinant antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
  • chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.
  • antibodies of the invention can be used to isolate a polypeptide of the invention by standard techniques, such as affinity chromatography or immunoprecipitation.
  • a polypeptide-specific antibody can facilitate the purification of natural polypeptide from cells and of recombinantly produced polypeptide expressed in host cells.
  • an antibody specific for a polypeptide of the invention can be used to detect the polypeptide (e.g., in a cellular lysate, cell supernatant, or tissue sample) in order to evaluate the abundance and pattern of expression of the polypeptide.
  • Antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Antibody detection can be facilitated by coupling it to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable
  • radioactive material examples include I, I, S or H.
  • the present invention also pertains to a method of diagnosing or aiding in the diagnosis of a disease or condition associated with a GPCR gene or gene product in an individual.
  • Diagnostic assays can be designed for assessing GPCR gene expression, or for assessing activity of GPCR polypeptides of the invention.
  • the assays are used in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or condition associated with a GPCR, or a defect in a GPCR.
  • the invention also provides for prognostic (or predictive) assays for determining whether an individual is susceptible to a disease of condition associated with a GPCR, e.g., if an individual is at risk for addiction to an opoid. For example, mutations in the gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive pu ⁇ ose to thereby prophylactically treat an individual prior to the onset of symptoms associated with a susceptibility to a disease or condition associated with a GPCR.
  • Another aspect of the invention pertains to assays for monitoring the influence of agents (e.g., drugs, compounds or other agents) on the gene expression or activity of polypeptides of the invention, as well as to assays for identifying agents that bind to a polypeptides.
  • agents e.g., drugs, compounds or other agents
  • assays for identifying agents that bind to a polypeptides are described in further detail in the following sections.
  • nucleic acids, probes, primers, polypeptides and antibodies described herein can be used in methods of diagnosis of a susceptibility to a disease or condition associated with a GPCR, as well as in kits useful for diagnosis of a susceptibility to a disease or condition associated with a GPCR.
  • susceptibility to a disease or condition associated with a GPCR can be diagnosed by detecting a polymo ⁇ hism in a GPCR as described herein.
  • the polymo ⁇ hism can be a mutation in a GPCR, such as the insertion or deletion of a single nucleotide, or of more than one nucleotide, resulting in a frame shift mutation; the change of at least one nucleotide, resulting in a change in the encoded amino acid; the change of at least one nucleotide, resulting in the generation of a premature stop codon; the deletion of several nucleotides, resulting in a deletion of one or more amino acids encoded by the nucleotides; the insertion of one or several nucleotides, such as by unequal recombination or gene conversion, resulting in an interruption of the coding sequence of the gene; duplication of all or a part of the gene; transposition of all or a part of the gene; or rearrangement of all or
  • More than one such mutation may be present in a single gene.
  • sequence changes cause a mutation in the polypeptide encoded by a GPCR gene.
  • the mutation is a frame shift mutation
  • the frame shift can result in a change in the encoded amino acids, and/or can result in the generation of a premature stop codon, causing generation of a truncated polypeptide.
  • a polymo ⁇ hism associated with a susceptibility to a disease or condition associated with a GPCR can be a synonymous mutation in one or more nucleotides (i.e., a mutation that does not result in a change in the polypeptide encoded by a GPCR gene).
  • Such a polymo ⁇ hism may alter splicing sites, affect the stability or transport of mRNA, or otherwise affect the transcription or translation of the gene.
  • a GPCR gene that has any of the mutations described above is referred to herein as a "mutant gene.”
  • hybridization methods such as Southern analysis, Northern analysis, or in situ hybridizations, can be used (see Current
  • test sample a biological sample from a test subject (a "test sample") of genomic DNA, RNA, or cDNA, is obtained from an individual suspected of having, being susceptible to or predisposed for, or carrying a defect for, a susceptibility to a disease or condition associated with a GPCR (the test sample)
  • test individual The individual can be an adult, child, or fetus.
  • the test sample can be from any source which contains genomic DNA, such as a blood sample, sample of amniotic fluid, sample of cerebrospinal fluid, or tissue sample from skin, muscle, buccal or conjunctival mucosa, placenta, gastrointestinal tract or other organs.
  • a test sample of DNA from fetal cells or tissue can be obtained by appropriate methods, such as by amniocentesis or chorionic villus sampling.
  • the DNA, RNA, or cDNA sample is then examined to determine whether a polymo ⁇ hism in a GPCR is present, and/or to determine which splicing variant(s) encoded by the GPCR is present.
  • nucleic acid probe can be a DNA probe or an RNA probe; the nucleic acid probe can contain at least one polymo ⁇ hism in a GPCR or contains a nucleic acid encoding a particular splicing variant of a GPCR.
  • the probe can be any of the nucleic acid molecules described above (e.g., the gene, a fragment, a vector comprising the gene, a probe or primer, etc.).
  • a test sample containing a GPCR is contacted with at least one nucleic acid probe to form a hybridization sample.
  • a preferred probe for detecting mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic
  • the nucleic acid probe can be, for example, a full-length nucleic acid molecule, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to appropriate mRNA or genomic DNA.
  • the nucleic acid probe can be all or a portion of one of SEQ ID NO: 1
  • nucleic Acids of the Invention are described above (see e.g., probes and primers discussed under the heading, "Nucleic Acids of the Invention").
  • the hybridization sample is maintained under conditions that are sufficient to allow specific hybridization of the nucleic acid probe to a GPCR.
  • Specific hybridization indicates exact hybridization (e.g., with no mismatches). Specific hybridization can be performed under high stringency conditions or moderate stringency conditions, for example, as described above. In a particularly preferred embodiment, the hybridization conditions for specific hybridization are high stringency. Specific hybridization, if present, is then detected using standard methods. If specific hybridization occurs between the nucleic acid probe and the GPCR in the test sample, then the GPCR has the polymo ⁇ hism, or is the splicing variant, that is present in the nucleic acid probe. More than one nucleic acid probe can also be used concurrently in this method.
  • nucleic acid probes Specific hybridization of any one of the nucleic acid probes is indicative of a polymo ⁇ hism in the GPCR, or of the presence of a particular splicing variant encoding the GPCR and is therefore diagnostic for a susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • RNA is obtained from the individual by appropriate means.
  • Specific hybridization of a nucleic acid probe, as described above, to RNA from the individual is indicative of a polymo ⁇ hism in a GPCR, or of the presence of a particular splicing variant encoded by a GPCR, and is therefore diagnostic for a susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • PNA peptide nucleic acid
  • a peptide nucleic acid (PNA) probe can be used instead of a nucleic acid probe in the hybridization methods described above.
  • PNA is a DNA mimic having a peptide-like, inorganic backbone, such as N-(2-aminoethyl)glycine units, with an organic base (A, G, C, T or U) attached to the glycine nitrogen via a methylene carbonyl linker (see, for example, Nielsen, P.E. et al, Bioconjugate Chemistry 5, American Chemical Society, p. 1 (1994).
  • the PNA probe can be designed to specifically hybridize to a gene having a polymo ⁇ hism associated with a susceptibility to a susceptibility to a disease or condition associated with a GPCR. Hybridization of the PNA probe to a GPCR is diagnostic for a susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • mutation analysis by restriction digestion can be used to detect a mutant gene, or genes containing a polymo ⁇ hism(s), if the mutation or polymo ⁇ hism in the gene results in the creation or elimination of a restriction site.
  • a test sample containing genomic DNA is obtained from the individual.
  • Polymerase chain reaction (PCR) can be used to amplify a GPCR (and, if necessary, the flanking sequences) in the test sample of genomic DNA from the test individual.
  • RFLP analysis is conducted as described (see Current Protocols in Molecular Biology, supra). The digestion pattern of the relevant DNA fragment indicates the presence or absence of the mutation or polymo ⁇ hism in the GPCR, and therefore indicates the presence or absence of this susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • Sequence analysis can also be used to detect specific polymo ⁇ hisms in a GPCR.
  • a test sample of DNA or RNA is obtained from the test individual.
  • PCR or other appropriate methods can be used to amplify the gene, and/or its flanking sequences, if desired.
  • the sequence of a GPCR, or a fragment of the gene, or cDNA, or fragment of the cDNA, or mRNA, or fragment of the mRNA, is determined, using standard methods.
  • the sequence of the gene, gene fragment, cDNA, cDNA fragment, mRNA, or mRNA fragment is compared with the known nucleic acid sequence of the gene, cDNA (e.g., one or more of SEQ ID NOs: 1-124 (odd numbers), or a complement thereof, or a nucleic acid sequence encoding one of SEQ ID NOs: 1-124 (even numbers) or a fragment thereof) or mRNA, as appropriate.
  • the presence of a polymo ⁇ hism in the GPCR indicates that the individual has a susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • Allele-specific oligonucleotides can also be used to detect the presence of a polymo ⁇ hism in a GPCR, through the use of dot-blot hybridization of amplified oligonucleotides with allele-specific oligonucleotide (ASO) probes (see, for example, Saiki, R. et al, Nature 324:163-166 (1986)).
  • ASO allele-specific oligonucleotide
  • an “allele-specific oligonucleotide” (also referred to herein as an “allele-specific oligonucleotide probe”) is an oligonucleotide of approximately 10-50 base pairs, preferably approximately 15-30 base pairs, that specifically hybridizes to a GPCR, and that contains a polymo ⁇ hism associated with a susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • An allele-specific oligonucleotide probe that is specific for particular polymo ⁇ hisms in a GPCR can be prepared, using standard methods (see Current Protocols in Molecular Biology, supra).
  • a test sample of DNA is obtained from the individual.
  • PCR can be used to amplify all or a fragment of a GPCR, and its flanking sequences.
  • the DNA containing the amplified GPCR (or fragment of the gene) is dot-blotted, using standard methods (see Current Protocols in Molecular Biology, supra), and the blot is contacted with the oligonucleotide probe. The presence of specific hybridization of the probe to the amplified GPCR is then detected.
  • Specific hybridization of an allele-specific oligonucleotide probe to DNA from the individual is indicative of a polymo ⁇ hism in the GPCR, and is therefore indicative of a susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual can be used to identify polymo ⁇ hisms in a GPCR.
  • an oligonucleotide array can be used.
  • Oligonucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. These oligonucleotide arrays, also described as "GenechipsTM,” have been generally described in the art, for example, U.S. Pat. No. 5,143,854 and PCT patent publication Nos. WO 90/15070 and 92/10092.
  • arrays can generally be produced using mechanical synthesis methods or light directed synthesis methods which inco ⁇ orate a combination of photolithographic methods and solid phase oligonucleotide synthesis methods. See Fodor et al, Science 251:767-777 (1991), Pirrung et al, U.S. Pat. No. 5,143,854 (see also PCT Application No. WO 90/15070) and Fodor et al, PCT Publication No. WO 92/10092 and U.S. Pat. No. 5,424,186, the entire teachings of each of which are inco ⁇ orated by reference herein. Techniques for the synthesis of these arrays using mechanical synthesis methods are described in, e.g., U.S. Pat. Nos. 5,384,261; the entire teachings of which are inco ⁇ orated by reference herein.
  • a nucleic acid of interest is hybridized with the array and scanned for polymo ⁇ hisms.
  • Hybridization and scanning are generally carried out by methods described herein and also in, e.g. ,
  • a target nucleic acid sequence that includes one or more previously identified polymo ⁇ hic markers is amplified by well known amplification techniques, e.g., PCR. Typically, this involves the use of primer sequences that are complementary to the two strands of the target sequence both upstream and downstream from the polymo ⁇ hism. Asymmetric PCR techniques may also be used.
  • Amplified target generally inco ⁇ orating a label, is then hybridized with the array under appropriate conditions. Upon completion of hybridization and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes.
  • the hybridization data obtained from the scan is typically in the form of fluorescence intensities as a function of location on the array.
  • arrays can include multiple detection blocks, and thus be capable of analyzing multiple, specific polymo ⁇ hisms.
  • detection blocks may be grouped within a single array or in multiple, separate arrays so that varying, optimal conditions may be used during the hybridization of the target to the array. For example, it may often be desirable to provide for the detection of those polymo ⁇ hisms that fall within G-C rich stretches of a genomic sequence, separately from those falling in A-T rich segments. This allows for the separate optimization of hybridization conditions for each situation.
  • nucleic acid analysis can be used to detect polymo ⁇ hisms in a GPCR or variants encoding by a GPCR.
  • Representative methods include direct manual sequencing (Church and Gilbert, Proc. Natl. Acad. Sci. USA 81:1991-1995 (1988); Sanger, F. et al. Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977); Beavis et al, U.S. Pat. No. 5,288,644); automated fluorescent sequencing; single-stranded conformation polymo ⁇ hism assays (SSCP); clamped denaturing gel electrophoresis (CDGE); denaturing gradient gel electrophoresis (DGGE) (Sheffield, V.C. et al.
  • diagnosis of a susceptibility to a susceptibility to a disease or condition associated with a GPCR can also be made by examining expression and/or composition of a GPCR polypeptide, by a variety of methods, including enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
  • ELISAs enzyme linked immunosorbent assays
  • a test sample from an individual is assessed for the presence of an alteration in the expression and/or an alteration in composition of the polypeptide encoded by a GPCR, or for the presence of a particular variant encoded by a GPCR.
  • An alteration in expression of a polypeptide encoded by a GPCR can be, for example, an alteration in the quantitative polypeptide expression (i.e., the amount of polypeptide produced); an alteration in the composition of a polypeptide encoded by a GPCR is an alteration in the qualitative polypeptide expression (e.g., expression of a mutant GPCR polypeptide or of a different splicing variant).
  • diagnosis of a susceptibility to a disease or condition associated with a GPCR is made by detecting a particular splicing variant encoded by that GPCR, or a particular pattern of splicing variants.
  • An "alteration" in the polypeptide expression or composition refers to an alteration in expression or composition in a test sample, as compared with the expression or composition of polypeptide by a GPCR in a control sample.
  • a control sample is a sample that corresponds to the test sample (e.g., is from the same type of cells), and is from an individual who is not affected by a susceptibility to a disease or condition associated with a GPCR.
  • An alteration in the expression or composition of the polypeptide in the test sample, as compared with the control sample is indicative of a susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • the presence of one or more different splicing variants in the test sample, or the presence of significantly different amounts of different splicing variants in the test sample, as compared with the control sample, is indicative of a susceptibility to a susceptibility to a disease or condition associated with a GPCR.
  • Various means of examining expression or composition of the polypeptide encoded by a GPCR can be used, including speetroscopy, colorimetry, electrophoresis, isoelectric focusing, and immunoassays (e.g., David et al, U.S. Pat. No. 4,376,110) such as immunoblotting (see also Current Protocols in Molecular Biology, particularly Chapter 10).
  • an antibody capable of binding to the polypeptide e.g., as described above
  • Antibodies can be polyclonal, or more preferably, monoclonal.
  • An intact antibody, or a fragment thereof e.g., Fab or F(ab') 2
  • the term "labeled", with regard to the probe or antibody is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
  • Western blotting analysis using an antibody as described above that specifically binds to a polypeptide encoded by a mutant GPCR, or an antibody that specifically binds to a polypeptide encoded by a non-mutant gene, or an antibody that specifically binds to a particular splicing variant encoded by a GPCR, can be used to identify the presence in a test sample of a particular splicing variant or of a polypeptide encoded by a polymo ⁇ hic or mutant GPCR, or the absence in a test sample of a particular splicing variant or of a polypeptide encoded by a non- polymo ⁇ hic or non-mutant gene.
  • the presence of a polypeptide encoded by a polymo ⁇ hic or mutant gene, or the absence of a polypeptide encoded by a non- polymo ⁇ hic or non-mutant gene, is diagnostic for a susceptibility to a susceptibility to a disease or condition associated with a GPCR, as is the presence (or absence) of particular splicing variants encoded by the GPCR gene.
  • the level or amount of polypeptide encoded by a GPCR in a test sample is compared with the level or amount of the polypeptide encoded by the GPCR in a control sample.
  • a level or amount of the polypeptide in the test sample that is higher or lower than the level or amount of the polypeptide in the control sample, such that the difference is statistically significant, is indicative of an alteration in the expression of the polypeptide encoded by the
  • the composition of the polypeptide encoded by a GPCR in a test sample is compared with the composition of the polypeptide encoded by the GPCR in a control sample (e.g., the presence of different splicing variants).
  • a difference in the composition of the polypeptide in the test sample, as compared with the composition of the polypeptide in the control sample is diagnostic for a susceptibility to a susceptibility to a disease or condition associated with that GPCR.
  • both the level or amount and the composition of the polypeptide can be assessed in the test sample and in the control sample.
  • a difference in the amount or level of the polypeptide in the test sample, compared to the control sample; a difference in composition in the test sample, compared to the control sample; or both a difference in the amount or level, and a difference in the composition, is indicative of a susceptibility to a susceptibility to a disease or condition associated with that GPCR.
  • Kits e.g.
  • reagent kits useful in the methods of diagnosis comprise components useful in any of the methods described herein, including for example, hybridization probes or primers as decribed herein (e.g., labeled probes or primers), reagents for detection of labeled molecules, restriction enzymes (e.g., for RFLP analysis), allele-specific oligonucleotides, antibodies which bind to mutant or to non-mutant (native) GPCR polypeptide, means for amplification of nucleic acids comprising a GPCR, or means for analyzing the nucleic acid sequence of a GPCR or for analyzing the amino acid sequence of a GPCR polypeptide, etc.
  • hybridization probes or primers as decribed herein e.g., labeled probes or primers
  • restriction enzymes e.g., for RFLP analysis
  • allele-specific oligonucleotides e.g., antibodies which bind to mutant or to non-mutant (native) GPCR polypeptide
  • the invention provides methods (also referred to herein as “screening assays”) for identifying the presence of a nucleotide that hybridizes to a nucleic acid of the invention, as well as for identifying the presence of a polypeptide encoded by a nucleic acid of the invention.
  • the presence (or absence) of a nucleic acid molecule of interest in a sample can be assessed by contacting the sample with a nucleic acid comprising a nucleic acid of the invention (e.g., a nucleic acid having the sequence of one of SEQ ID NOs: 1-124 (odd numbers), or the complement thereof, or a nucleic acid encoding an amino acid having the sequence of one of SEQ ID NOs:l-124 (even numbers), or a fragment or variant of such nucleic acids), under stringent conditions as described above, and then assessing the sample for the presence (or absence) of hybridization.
  • a nucleic acid comprising a nucleic acid of the invention e.g., a nucleic acid having the sequence of one of SEQ ID NOs: 1-124 (odd numbers), or the complement thereof, or a nucleic acid encoding an amino acid having the sequence of one of SEQ ID NOs:l-124 (even numbers), or a fragment or variant of such nucleic acids
  • high stringency conditions are conditions appropriate for selective hybridization.
  • a sample containing the nucleic acid molecule of interest is contacted with a nucleic acid containing a contiguous nucleotide sequence (e.g., a primer or a probe as described above) that is at least partially complementary to a part of the nucleic acid molecule of interest (e.g., a GPCR nucleic acid), and the contacted sample is assessed for the presence or absence of hybridization.
  • the nucleic acid containing a contiguous nucleotide sequence is completely complementary to a part of the nucleic acid molecule of interest.
  • all or a portion of the nucleic acid of interest can be subjected to amplification prior to performing the hybridization.
  • the presence (or absence) of a polypeptide of interest, such as a polypeptide of the invention or a fragment or variant thereof, in a sample can be assessed by contacting the sample with an antibody that specifically hybridizes to the polypeptide of interest (e.g., an antibody such as those described above), and then assessing the sample for the presence (or absence) of binding of the antibody to the polypeptide of interest.
  • an antibody that specifically hybridizes to the polypeptide of interest e.g., an antibody such as those described above
  • the invention provides methods for identifying agents
  • polypeptides e.g., fusion proteins, polypeptides, peptidomimetics, prodrugs, other receptors associated with GPCRs, binding agents, antibodies, small molecules or other drugs, or ribozymes which alter (e.g., increase or decrease) the activity of the polypeptides described herein, or which otherwise interact with the polypeptides herein.
  • fusion proteins e.g., fusion proteins, polypeptides, peptidomimetics, prodrugs, other receptors associated with GPCRs, binding agents, antibodies, small molecules or other drugs, or ribozymes which alter (e.g., increase or decrease) the activity of the polypeptides described herein, or which otherwise interact with the polypeptides herein.
  • such agents can be agents which bind to polypeptides described herein (e.g., GPCR binding agents); which have a stimulatory or inhibitory effect on, for example, activity of polypeptides of the invention; or which change (e.g., enhance or inhibit) the ability of the polypeptides of the invention to interact with GPCR binding agents (e.g, G-proteins, other receptors associated with GPCRs, or other binding agents); or which alter posttranslational processing of the GPCR polypeptide (e.g., agents that alter proteolytic processing to direct the polypeptide from where it is normally synthesized to another location in the cell, such as the cell surface; agents that alter proteolytic processing such that more polypeptide is released from the cell, etc.
  • GPCR binding agents e.g, G-proteins, other receptors associated with GPCRs, or other binding agents
  • alter posttranslational processing of the GPCR polypeptide e.g., agents that alter proteolytic processing to direct the polypeptide from where it is normally synthesized
  • the invention provides assays for screening candidate or test agents that bind to or modulate the activity of polypeptides described herein (or biologically active portion(s) thereof), as well as agents identifiable by the assays.
  • Test agents can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection.
  • the biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. , Anticancer Drug Des. 12: 145 (1997)).
  • a cell, cell lysate, or solution containing or expressing a GPCR polypeptide e.g., one of SEQ ID NOs:l-124 (even numbers), or another splicing variant encoded by a GPCR), or a fragment or derivative thereof (as described above)
  • a GPCR polypeptide e.g., one of SEQ ID NOs:l-124 (even numbers), or another splicing variant encoded by a GPCR
  • a fragment or derivative thereof as described above
  • the level (amount) of GPCR activity is assessed (e.g., the level (amount) of GPCR activity is measured, either directly or indirectly), and is compared with the level of activity in a control (i.e., the level of activity of the GPCR polypeptide or active fragment or derivative thereof in the absence of the agent to be tested). If the level of the activity in the presence of the agent differs, by an amount that is statistically significant, from the level of the activity in the absence of the agent, then the agent is an agent that alters the activity of a GPCR polypeptide. An increase in the level of GPCR activity relative to a control, indicates that the agent is an agent that enhances (is an agonist of) GPCR activity.
  • a decrease in the level of GPCR activity relative to a control indicates that the agent is an agent that inhibits (is an antagonist of) GPCR activity.
  • the level of activity of a GPCR polypeptide or derivative or fragment thereof in the presence of the agent to be tested is compared with a control level that has previously been established. A level of the activity in the presence of the agent that differs from the control level by an amount that is statistically significant indicates that the agent alters GPCR activity.
  • the present invention also relates to an assay for identifying agents which alter the expression of a GPCR gene (e.g., antisense nucleic acids, fusion proteins, polypeptides, peptidomimetics, prodrugs, other receptors associated with GPCRs, G- proteins, binding agents, antibodies, small molecules or other drugs, or ribozymes) which alter (e.g. , increase or decrease) expression (e.g. , transcription or translation) of the gene or which otherwise interact with the nucleic acids described herein, as well as agents identifiable by the assays.
  • a solution containing a nucleic acid encoding a GPCR polypeptide e.g, a GPCR gene
  • an agent to be tested e.g., antisense nucleic acids, fusion proteins, polypeptides, peptidomimetics, prodrugs, other receptors associated with GPCRs, G- proteins, binding agents, antibodies, small molecules or other drugs, or ribozymes
  • the solution can comprise, for example, cells containing the nucleic acid or cell lysate containing the nucleic acid; alternatively, the solution can be another solution mat comprises elements necessary for transcription/translation of the nucleic acid. Cells not suspended in solution can also be employed, if desired.
  • the level and/or pattern of GPCR expression e.g., the level and/or pattern of mRNA or of protein expressed, such as the level and/or pattern of different splicing variants
  • a control i.e., the level and/or pattern of the GPCR expression in the absence of the agent to be tested.
  • the agent is an agent that alters the expression of GPCR.
  • Enhancement of GPCR expression indicates that the agent is an agonist of GPCR activity.
  • inhibition of GPCR expression indicates that the agent is an antagonist of GPCR activity.
  • the level and/or pattern of GPCR polypeptide(s) e.g., different splicing variants
  • the level and/or pattern of GPCR polypeptide(s) is compared with a control level and/or pattern that have previously been established. A level and/or pattern in the presence of the agent that differs from the control level and/or pattern by an amount or in a manner that is statistically significant indicates that the agent alters GPCR expression.
  • agents which alter the expression of a GPCR gene or which otherwise interact with the nucleic acids described herein can be identified using a cell, cell lysate, or solution containing a nucleic acid encoding the promoter region of the GPCR gene operably linked to a reporter gene.
  • the level of expression of the reporter gene e.g., the level of mRNA or of protein expressed
  • z ' the level of the expression of the reporter gene in the absence of the agent to be tested. If the level in the presence of the agent differs, by an amount or in a manner that is statistically significant, from the level in the absence of the agent, then the agent is an agent that alters the expression of the
  • GPCR as indicated by its ability to alter expression of a gene that is operably linked to the GPCR gene promoter. Enhancement of the expression of the reporter indicates that the agent is an agonist of GPCR activity. Similarly, inhibition of the expression of the reporter indicates that the agent is an antagonist of GPCR activity.
  • the level of expression of the reporter in the presence of the agent to be tested is compared with a control level that has previously been established. A level in the presence of the agent that differs from the control level by an amount or in a manner that is statistically significant indicates that the agent alters expression. Agents which alter the amounts of different splicing variants encoded by a
  • GPCR e.g., an agent which enhances activity of a first splicing variant, and which inhibits activity of a second splicing variant
  • agents which are agonists of activity of a first splicing variant and antagonists of activity of a second splicing variant can easily be identified using these methods described above.
  • assays can be used to assess the impact of a test agent on the activity of a polypeptide in relation to a GPCR binding agent.
  • a cell that expresses a compound that interacts with a GPCR (herein referred to as a "GPCR binding agent", which can be a polypeptide or other molecule that interacts with a GPCR, such as a G-protein) is contacted with a GPCR in the presence of a test agent, and the ability of the test agent to alter the interaction between the GPCR and the GPCR binding agent is determined.
  • a cell lysate or a solution containing the GPCR binding agent can be used.
  • An agent which binds to the GPCR or the GPCR binding agent can alter the interaction by interfering with, or enhancing the ability of the GPCR to bind to, associate with, or otherwise interact with the GPCR binding agent.
  • Determining the ability of the test agent to bind to a GPCR or a GPCR binding agent can be accomplished, for example, by coupling the test agent with a radioisotope or enzymatic label such that binding of the test agent to the polypeptide can be determined by detecting the
  • test agents can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. It is also within the scope of this invention to determine the ability of a test agent to interact with the polypeptide without the labeling of any of the interactants.
  • a microphysiometer can be used to detect the interaction of a test agent with a GPCR or a GPCR binding agent without the labeling of either the test agent, GPCR, or the GPCR binding agent. McConnell, H.M. et al. , Science 257:1906-
  • a "microphysiometer” e.g., CytosensorTM
  • LAPS light-addressable potentiometric sensor
  • Changes in this acidification rate can be used as an indicator of the interaction between ligand and polypeptide.
  • these receptors can be used to screen for compounds that are agonists for use in treating a susceptibility to a disease or condition associated with a GPCR or antagonists for studying a susceptibility to a disease or condition associated with a GPCR.
  • Drugs could be designed to regulate GPCR activation that in turn can be used to regulate signaling pathways and transcription events of genes downstream.
  • assays can be used to identify polypeptides that interact with one or more GPCR polypeptides, as described herein.
  • a yeast two-hybrid system such as that described by Fields and Song (Fields, S. and Song, O., Nature 340:245-246 (1989)) can be used to identify polypeptides that interact with one or more GPCR polypeptides.
  • vectors are constructed based on the flexibility of a transcription factor that has two functional domains (a DNA binding domain and a transcription activation domain).
  • transcriptional activation can be achieved, and transcription of specific markers (e.g, nutritional markers such as His and Ade, or color markers such as lacZ) can be used to identify the presence of interaction and transcriptional activation.
  • specific markers e.g, nutritional markers such as His and Ade, or color markers such as lacZ
  • a first vector which includes a nucleic acid encoding a DNA binding domain and also a GPCR polypeptide, splicing variant, or fragment or derivative thereof
  • a second vector is used which includes a nucleic acid encoding a transcription activation domain and also a nucleic acid encoding a polypeptide which potentially may interact with the GPCR polypeptide, splicing variant, or fragment or derivative thereof (e.g., a GPCR polypeptide binding agent or G-protein).
  • incubation of yeast containing the first vector and the second vector under appropriate conditions (e.g., mating conditions such as used in the MatchmakerTM system from Clontech (Palo
  • binding of a test agent to the polypeptide, or interaction of the polypeptide with a binding agent in the presence and absence of a test agent can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes.
  • a fusion protein e.g., a glutathione-S-transferase fusion protein
  • a fusion protein e.g., a glutathione-S-transferase fusion protein
  • modulators of expression of nucleic acid molecules of the invention are identified in a method wherein a cell, cell lysate, or solution containing a nucleic acid encoding a GPCR is contacted with a test agent and the expression of appropriate mRNA or polypeptide (e.g., splicing variant(s)) in the cell, cell lysate, or solution, is determined.
  • appropriate mRNA or polypeptide e.g., splicing variant(s)
  • the level of expression of appropriate mRNA or polypeptide(s) in the presence of the test agent is compared to the level of expression of mRNA or polypeptide(s) in the absence of the test agent.
  • the test agent can then be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater (statistically significantly greater) in the presence of the test agent than in its absence, the test agent is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less (statistically significantly less) in the presence of the test agent than in its absence, the test agent is identified as an inhibitor of the mRNA or polypeptide expression.
  • the level of mRNA or polypeptide expression in the cells can be determined by methods described herein for detecting mRNA or polypeptide.
  • This invention further pertains to novel agents identified by the above- described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model.
  • an agent identified as described herein e.g., a test agent that is a modulating agent, an antisense nucleic acid molecule, a specific antibody, or a polypeptide-binding agent
  • an agent identified as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
  • an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent.
  • this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.
  • an agent identified as described herein can be used to alter activity of a polypeptide encoded by a GPCR, or to alter expression of a GPCR, by contacting the polypeptide or the gene (or contacting a cell comprising the polypeptide or the gene) with the agent identified as described herein.
  • the present invention also pertains to pharmaceutical compositions comprising nucleic acids described herein, particularly nucleotides encoding the polypeptides described herein; comprising polypeptides described herein (e.g., one or more of SEQ ID NOs:l-124 (even numbers)); and/or comprising other splicing variants encoded by a GPCR; and/or an agent that alters (e.g., enhances or inhibits) GPCR gene expression or GPCR polypeptide activity as described herein.
  • nucleic acids described herein particularly nucleotides encoding the polypeptides described herein; comprising polypeptides described herein (e.g., one or more of SEQ ID NOs:l-124 (even numbers)); and/or comprising other splicing variants encoded by a GPCR; and/or an agent that alters (e.g., enhances or inhibits) GPCR gene expression or GPCR polypeptide activity as described herein.
  • a polypeptide, protein e.g., a G-protein
  • an agent that alters GPCR gene expression or a GPCR binding agent or binding partner, fragment, fusion protein or prodrug thereof, or a nucleotide or nucleic acid construct (vector) comprising a nucleotide of the present invention, or an agent that alters GPCR polypeptide activity
  • a physiologically acceptable carrier or excipient can be formulated with a physiologically acceptable carrier or excipient to prepare a pharmaceutical composition.
  • the carrier and composition can be sterile.
  • the formulation should suit the mode of admimstration.
  • Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions (e.g., NaCl), saline, buffered saline, alcohols, glycerol, ethanol, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, dextrose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrolidone, etc., as well as combinations thereof.
  • the pharmaceutical preparations can, if desired, be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active agents.
  • auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active agents.
  • the composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrollidone, sodium saccharine, cellulose, magnesium carbonate, etc.
  • compositions for introduction of these compositions include, but are not limited to, intradermal, intramuscular, intraperitoneal, intraocular, intravenous, subcutaneous, topical, oral and intranasal.
  • Other suitable methods of introduction can also include gene therapy (as described below), rechargeable or biodegradable devices, particle acceleration devises ("gene guns") and slow release polymeric devices.
  • the pharmaceutical compositions of this invention can also be administered as part of a combinatorial therapy with other agents.
  • the composition can be formulated in accordance with the routine procedures as a pharmaceutical composition adapted for administration to human beings.
  • compositions for intravenous administration typically are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent.
  • the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose/water.
  • an ampule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to admimstration.
  • nonsprayable forms viscous to semi-solid or solid forms comprising a carrier compatible with topical application and having a dynamic viscosity preferably greater than water
  • Suitable formulations include but are not limited to solutions, suspensions, emulsions, creams, ointments, powders, enemas, lotions, sols, liniments, salves, aerosols, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, wetting agents, buffers or salts for influencing osmotic pressure, etc.
  • the agent may be inco ⁇ orated into a cosmetic formulation.
  • sprayable aerosol preparations wherein the active ingredient, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant, e.g., pressurized air.
  • a pressurized volatile, normally gaseous propellant e.g., pressurized air.
  • Agents described herein can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
  • the agents are administered in a therapeutically effective amount.
  • the amount of agents which will be therapeutically effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques.
  • in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the symptoms of a susceptibility to a disease or condition associated with a GPCR, and should be decided according to the judgment of a practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use of sale for human administration.
  • the pack or kit can be labeled with information regarding mode of administration, sequence of drug administration (e.g., separately, sequentially or concurrently), or the like.
  • the pack or kit may also include means for reminding the patient to take the therapy.
  • the pack or kit can be a single unit dosage of the combination therapy or it can be a plurality of unit dosages.
  • the agents can be separated, mixed together in any combination, present in a single vial or tablet.
  • Agents assembled in a blister pack or other dispensing means is preferred.
  • unit dosage is intended to mean a dosage that is dependent on the individual pharmacodynamics of each agent and administered in FDA approved dosages in standard time courses.
  • the present invention also pertains to methods of treatment (prophylactic and or therapeutic) for a susceptibility to a disease or condition associated with a GPCR, using a GPCR therapeutic agent.
  • GPCR therapeutic agent is an agent that alters (e.g., enhances or inhibits) GPCR polypeptide activity and/or GPCR gene expression, as described herein (e.g., a GPCR agonist or antagonist).
  • GPCR therapeutic agents can alter GPCR polypeptide activity or gene expression by a variety of means, such as, for example, by providing additional GPCR polypeptide or by upregulating the transcription or translation of the GPCR gene; by altering posttranslational processing of the GPCR polypeptide; by altering transcription of GPCR splicing variants; or by interfering with GPCR polypeptide activity (e.g., by binding to a GPCR polypeptide), or by downregulating the transcription or translation of a GPCR gene.
  • GPCR therapeutic agents include the following: nucleic acids or fragments or derivatives thereof described herein, particularly nucleotides encoding the polypeptides described herein and vectors comprising such nucleic acids (e.g., a gene, cDNA, and/or mRNA, such as a nucleic acid encoding a GPCR polypeptide or active fragment or derivative thereof, or an oligonucleotide; for example, one of SEQ ID NOs: 1-124 (odd numbers), or a complement thereof, or a nucleic acid encoding one of SEQ ID NOs: 1-124 (even numbers), or fragments or derivatives thereof); polypeptides described herein (e.g, one or more of SEQ ID NOs: 1-124 (even numbers), and/or other splicing variants encoded by a GPCR, or fragments or derivatives thereof); other polypeptides (e.g., G-proteins); GPCR binding agents; peptidomimetics; fusion proteins or prodrugs thereof
  • More than one GPCR therapeutic agent can be used concurrently, if desired.
  • a GPCR therapeutic agent that is a nucleic acid is used in the treatment of a susceptibility to a disease or condition associated with a GPCR.
  • treatment refers not only to ameliorating symptoms associated with the disease, but also preventing or delaying the onset of the disease, and also lessening the severity or frequency of symptoms of the disease.
  • the therapy is designed to alter (e.g., inhibit or enhance), replace or supplement activity of a GPCR polypeptide in an individual.
  • a GPCR therapeutic agent can be administered in order to upregulate or increase the expression or availability of the GPCR gene or of specific splicing variants of GPCR, or, conversely, to downregulate or decrease the expression or availability of the GPCR gene or specific splicing variants of the GPCR.
  • Upregulation or increasing expression or availability of a native GPCR gene or of a particular splicing variant could interfere with or compensate for the expression or activity of a defective gene or another splicing variant; downregulation or decreasing expression or availability of a native GPCR gene or of a particular splicing variant could minimize the expression or activity of a defective gene or the particular splicing variant and thereby minimize the impact of the defective gene or the particular splicing variant.
  • the GPCR therapeutic agent(s) are administered in a therapeutically effective amount (i.e., an amount that is sufficient to treat the disease, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and or also lessening the severity or frequency of symptoms of the disease).
  • a therapeutically effective amount i.e., an amount that is sufficient to treat the disease, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and or also lessening the severity or frequency of symptoms of the disease.
  • the amount which will be therapeutically effective in the treatment of a particular individual's disorder or condition will depend on the symptoms and severity of the disease, and can be determined by standard clinical techniques.
  • in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of a practitioner and each patient's circumstances. Effective
  • a nucleic acid of the invention e.g., a nucleic acid encoding a GPCR polypeptide, such as one of SEQ ID NOs: 1-124 (odd numbers), or a complement thereof; or another nucleic acid that encodes a GPCR polypeptide or a splicing variant, derivative or fragment thereof, such as a nucleic acid encoding one of SEQ ID NOs: 1-124 (even numbers)
  • a nucleic acid of the invention can be used, either alone or in a pharmaceutical composition as described above.
  • a GPCR or a cDNA encoding a GPCR polypeptide can be introduced into cells (either in vitro or in vivo) such that the cells produce native GPCR polypeptide.
  • cells that have been transformed with the gene or cDNA or a vector comprising the gene or cDNA can be introduced (or re- introduced) into an individual affected with the disease.
  • cells which, in nature, lack native GPCR expression and activity, or have mutant GPCR expression and activity, or have expression of a disease-associated GPCR splicing variant can be engineered to express the GPCR polypeptide or an active fragment of the GPCR polypeptide (or a different variant of the GPCR polypeptide).
  • nucleic acid encoding a GPCR polypeptide, or an active fragment or derivative thereof can be introduced into an expression vector, such as a viral vector, and the vector can be introduced into appropriate cells in an animal.
  • an expression vector such as a viral vector
  • Other gene transfer systems including viral and nonviral transfer systems, can be used.
  • nonviral gene transfer methods such as calcium phosphate coprecipitation, mechanical techniques (e.g., microinjection); membrane fusion- mediated transfer via liposomes; or direct DNA uptake, can also be used.
  • a nucleic acid of the invention in another embodiment, can be used in "antisense" therapy, in which a nucleic acid (e.g., an oligonucleotide) which specifically hybridizes to the mRNA and or genomic DNA of a GPCR is administered or generated in situ.
  • the antisense nucleic acid that specifically hybridizes to the mRNA and/or DNA inhibits expression of the GPCR polypeptide, e.g., by inhibiting translation and/or transcription. Binding of the antisense nucleic acid can be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interaction in the major groove of the double helix.
  • an antisense construct of the present invention can be delivered, for example, as an expression plasmid as described above.
  • the plasmid When the plasmid is transcribed in the cell, it produces RNA that is complementary to a portion of the mRNA and/or DNA which encodes the GPCR polypeptide.
  • the antisense construct can be an oligonucleotide probe that is generated ex vivo and introduced into cells; it then inhibits expression by hybridizing with the mRNA and/or genomic DNA of the GPCR.
  • the oligonucleotide probes are modified oligonucleotides that are resistant to endogenous nucleases, e.g.
  • nucleic acid molecules for use as antisense oligonucleotides are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S. 5,176,996; 5,264,564; and 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense therapy are also described, for example, by Van der Krol et al, (Biotechniques 6:958-976 (1988)); and Stein et al. (Cancer Res. 48:2659-2668 (1988)).
  • oligodeoxyribonucleotides derived from the translation initiation site are preferred.
  • oligonucleotides mRNA, cDNA or DNA
  • the antisense oligonucleotides bind to GPCR mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required.
  • a sequence "complementary" to a portion of an RNA indicates that a sequence has sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed.
  • the ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid, as described in detail above. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be).
  • the oligonucleotides used in antisense therapy can be DNA, RNA, or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded.
  • the oligonucleotides can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc.
  • the oligonucleotides can include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al, Proc. Natl. Acad. Sci.
  • the oligonucleotide may be conjugated to another molecule (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent).
  • the antisense molecules are delivered to cells that express GPCR in vivo.
  • a number of methods can be used for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.
  • a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong promoter (e.g., pol HI or pol TT).
  • a strong promoter e.g., pol HI or pol TT.
  • the use of such a construct to transfect target cells in the patient results in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous GPCR transcripts and thereby prevent translation of the GPCR mRNA.
  • a vector can be introduced in vivo such that it is taken up in a cell and directs the transcription of an antisense RNA.
  • Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.
  • Such vectors can be constructed by recombinant DNA technology methods standard in the art and described above.
  • a plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct that can be introduced directly into the tissue site.
  • viral vectors can be used which selectively infect the desired tissue, in which case administration may be accomplished by another route (e.g., systemically).
  • Endogenous GPCR expression can be reduced by inactivating or "knocking out” GPCR or its promoter using targeted homologous recombination (e.g., see Smithies et al, Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512
  • a mutant, nonfunctional GPCR flanked by DNA homologous to the endogenous GPCR (either the coding regions or regulatory regions of GPCR) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the GPCR in vivo. Insertion of the
  • the recombinant DNA constructs can be directly administered or targeted to the required site in vivo using appropriate vectors, as described above.
  • expression of non-mutant GPCRs can be increased using a similar method: targeted homologous recombination can be used to insert a DNA construct comprising a non-mutant, functional GPCR, e.g., a gene having one of SEQ ED NOs: 1-124 (odd numbers), or the complement thereof, or a portion thereof, in place of a mutant GPCR in the cell, as described above.
  • targeted homologous recombination can be used to insert a DNA construct comprising a nucleic acid that encodes a GPCR polypeptide variant that differs from that present in the cell.
  • endogenous GPCR expression can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of a GPCR (i.e., the GPCR promoter and/or enhancers) to form triple helical structures that prevent transcription of the GPCR in target cells in the body.
  • deoxyribonucleotide sequences complementary to the regulatory region of a GPCR i.e., the GPCR promoter and/or enhancers
  • the antisense constructs described herein by antagonizing the normal biological activity of one of the GPCR proteins, can be used in the manipulation of tissue, e.g., tissue differentiation, both in vivo and for ex vivo tissue cultures.
  • anti-sense techniques e.g., microinjection of antisense molecules, or transfection with plasmids whose transcripts are anti-sense with regard to a GPCR mRNA or gene sequence
  • Such techniques can be utilized in cell culture, but can also be used in the creation of transgenic animals.
  • GPCR therapeutic agents as described herein can also be used in the treatment or prevention of a susceptibility to a disease or condition associated with a GPCR.
  • the therapeutic agents can be delivered in a composition, as described above, or by themselves. They can be administered systemically, or can be targeted to a particular tissue.
  • the therapeutic agents can be produced by a variety of means, including chemical synthesis; recombinant production; in vivo production (e.g., a transgenic animal, such as U.S.
  • a combination of any of the above methods of treatment e.g., administration of non-mutant GPCR polypeptide in conjunction with antisense therapy targeting mutant GPCR mRNA; administration of a first splicing variant encoded by a GPCR in conjunction with antisense therapy targeting a second splicing encoded by a GPCR
  • administration of non-mutant GPCR polypeptide in conjunction with antisense therapy targeting mutant GPCR mRNA e.g., administration of non-mutant GPCR polypeptide in conjunction with antisense therapy targeting mutant GPCR mRNA
  • administration of a first splicing variant encoded by a GPCR in conjunction with antisense therapy targeting a second splicing encoded by a GPCR can also be used.
  • MOOSE00804 ctg30162 16180..16299, 37790..38066, 71494..71629, 82561..82975
  • SWELQMFFFM SLLYVATMVGNSLIVITV ⁇ VDPHLHSPMYFLLTNLS ⁇ DMSL ASFATPKMTDYLTGHKTISFDGCLTQIFFLHLFTGTE ⁇ LLMAMSFDRYIAICKPLHYA SVISPQVCVALWASWIMGVMHSMTPFIEYLLIRVSFLHCLSLLTLLKNSWLQVRGF GFCILFYCLSFTFSLLVSSY ⁇ ILVTVWLKSSAAMAKAFSTLASHIAVVTLFFGPCIFI
  • MOOSE00843 ctgl5064 31780507..31780654, 31841187..31841254, 31873514..31873564, 31907740..31907833, 31923371..31923572, 31930354..31930411, 31940910..31940952, 31944453..31944599, 32115413..32115576
  • MOOSE01139 ctgl26341689941..1690075, 1696196..1696364, 1729541..1729632, 1731449..1731515, 1744203..1744423, 1748034..1748243, 1777967..1778134, 1813481..1813504, 1865325..1865428, 1868201..1868336
  • MOOSE02352 ctgl23762508254..2508274, 2512637..2512697, 2596061..2596100, 2609217..2609251, 2697256..2697388, 2697901..2698120, 2702134..2702373, 2703765..2703914, 2704936..2705391, 2785876..2785900, 2796650..2796801
  • MOOSE05621 ctgl5361 27306427-27307048, 27307103-27307314,
  • SASQVAGTTGAPJfflARLFFLFLVET (SEQ ED NO: 108) aaccctgaaatgaatgttgtcctttctgtgctctttetattaatctatotcattactgtcttgggcaacttttggattatcataataattc tggctagtgcccaactccattcacccatgfactttttccttagccagftggcltt ⁇ ggtgaattacatagcaggacagaaaagtcatctcttatcacggttgcctccttcagtattcctttgtcagcttgttcctgactactgaatgcttc ctggctgccatggcatgtgatcggtatctcgctgtttgccacccacttcactacaacatagagtccaggagccaattagat
  • EREKEKERKERKEREKERKERKERKKE (SEQ ED NO: 112) ccatcaagaattgaccttttcttcttcattctcattgttttcattttcctgatggctctaattggaaacctgtccatgattcttctcatctt cttggacacccatctccacacacccatgtatttcctactgagtcagctctccctcattgacctaaattacatctccaccatttgttcctaagat ggcatctgattttctgcatggaaacaagtctatctctcactgggtgtgggattcagagtttctcttttggcattaggaggtgcagaagc actacttttggcatctatggcctatgatcgttacattgcttttttttt
  • MOOSE06051 ctgl5064 38069881-38070569, 38071866-38071965, 38089519-38089577, 38100385..38100508
  • MOOSE05863 Class A O ⁇ han other DISTANCE -1.97 Mb
  • MOOSE06011 Class A O ⁇ han other DISTANCE 8.000 Mb
  • MOOSE05784 Class A O ⁇ han other DISTANCE 0.959 Mb
  • MOOSE06049 Class A O ⁇ han other W.98O- ⁇ DNVXSi ⁇ lamo UBqdio V SSB lO S0__03SOOI ⁇ [ ⁇ c :do ⁇ p ⁇ OT gsnoo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des acides nucléiques codants pour des récepteurs couplés à une protéine G et des procédés d'utilisation de ceux-ci.
PCT/IB2002/002357 2001-06-26 2002-06-24 Acides nucleiques codants pour des recepteurs couples a une proteine g WO2003000893A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30109501P 2001-06-26 2001-06-26
US60/301,095 2001-06-26
US33318501P 2001-11-06 2001-11-06
US60/333,185 2001-11-06

Publications (2)

Publication Number Publication Date
WO2003000893A2 true WO2003000893A2 (fr) 2003-01-03
WO2003000893A3 WO2003000893A3 (fr) 2003-10-02

Family

ID=26972159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002357 WO2003000893A2 (fr) 2001-06-26 2002-06-24 Acides nucleiques codants pour des recepteurs couples a une proteine g

Country Status (1)

Country Link
WO (1) WO2003000893A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
US8324361B2 (en) 2005-10-31 2012-12-04 Oncomed Pharmaceuticals, Inc. Nucleic acid molecules encoding soluble frizzled (FZD) receptors
US8507442B2 (en) 2008-09-26 2013-08-13 Oncomed Pharmaceuticals, Inc. Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
US8522337B2 (en) 2001-10-23 2013-08-27 Intel Corporation Selecting a security format conversion for wired and wireless devices
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
US8796441B2 (en) 2005-04-13 2014-08-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human sweet and umami taste receptor variants
US9089556B2 (en) 2000-08-03 2015-07-28 The Regents Of The University Of Michigan Method for treating cancer using an antibody that inhibits notch4 signaling
US9157904B2 (en) 2010-01-12 2015-10-13 Oncomed Pharmaceuticals, Inc. Wnt antagonists and methods of treatment and screening
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9850311B2 (en) 2005-10-31 2017-12-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024282A1 (fr) * 1993-04-09 1994-10-27 Pfizer Inc. Recepteur de lymphocyte t humain appartenant a la famille des recepteurs couples a une proteine g
WO2001098351A2 (fr) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. Recepteurs couples a la proteine g

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10248582A (ja) * 1997-03-12 1998-09-22 Asahi Chem Ind Co Ltd 新規な７回膜貫通型受容体蛋白質ｊｅｇ１８

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024282A1 (fr) * 1993-04-09 1994-10-27 Pfizer Inc. Recepteur de lymphocyte t humain appartenant a la famille des recepteurs couples a une proteine g
WO2001098351A2 (fr) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. Recepteurs couples a la proteine g

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL3 April 2001 (2001-04-03) "Homo sapiens putative purinergic receptor (FKSG79) mRNA, complete cds." Database accession no. AF345567 XP002221770 *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 14, 31 December 1998 (1998-12-31) -& JP 10 248582 A (ASAHI CHEM IND CO LTD), 22 September 1998 (1998-09-22) *
STADEL J M ET AL: "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 18, no. 11, 1 November 1997 (1997-11-01), pages 430-437, XP004099345 ISSN: 0165-6147 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089556B2 (en) 2000-08-03 2015-07-28 The Regents Of The University Of Michigan Method for treating cancer using an antibody that inhibits notch4 signaling
US8522337B2 (en) 2001-10-23 2013-08-27 Intel Corporation Selecting a security format conversion for wired and wireless devices
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
US8796441B2 (en) 2005-04-13 2014-08-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human sweet and umami taste receptor variants
US9850311B2 (en) 2005-10-31 2017-12-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8765913B2 (en) 2005-10-31 2014-07-01 Oncomed Pharmaceuticals, Inc. Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells
US8324361B2 (en) 2005-10-31 2012-12-04 Oncomed Pharmaceuticals, Inc. Nucleic acid molecules encoding soluble frizzled (FZD) receptors
US9732139B2 (en) 2005-10-31 2017-08-15 Oncomed Pharmaceuticals, Inc. Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor
US9228013B2 (en) 2005-10-31 2016-01-05 OncoMed Pharmaceuticals Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell
US8507442B2 (en) 2008-09-26 2013-08-13 Oncomed Pharmaceuticals, Inc. Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
US8975044B2 (en) 2008-09-26 2015-03-10 Oncomed Pharmaceuticals, Inc. Polynucleotides encoding for frizzled-binding agents and uses thereof
US9273139B2 (en) 2008-09-26 2016-03-01 Oncomed Pharmaceuticals, Inc. Monoclonal antibodies against frizzled
US9573998B2 (en) 2008-09-26 2017-02-21 Oncomed Pharmaceuticals, Inc. Antibodies against human FZD5 and FZD8
US9157904B2 (en) 2010-01-12 2015-10-13 Oncomed Pharmaceuticals, Inc. Wnt antagonists and methods of treatment and screening
US9579361B2 (en) 2010-01-12 2017-02-28 Oncomed Pharmaceuticals, Inc. Wnt antagonist and methods of treatment and screening
US9499630B2 (en) 2010-04-01 2016-11-22 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9987357B2 (en) 2013-02-04 2018-06-05 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a WNT pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof

Also Published As

Publication number Publication date
WO2003000893A3 (fr) 2003-10-02

Similar Documents

Publication Publication Date Title
AU2010202722B2 (en) Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
US20020045577A1 (en) Human schizophrenia gene
WO2003000893A2 (fr) Acides nucleiques codants pour des recepteurs couples a une proteine g
JP2004508835A (ja) ヒト骨粗鬆症遺伝子
CA2502359A1 (fr) Gene de susceptibilite d'un infarctus du myocarde
WO2003000901A2 (fr) Acides nucleiques codant des proteines kinases
US20020094954A1 (en) Human schizophrenia gene
WO2003000735A2 (fr) Acides nucleiques codant pour des recepteurs olfactifs
WO2001046415A1 (fr) Polypeptides de type tachykinine et utilisation associee
EP1129103A1 (fr) Recepteur couple a la proteine g ressemblant au recepteur b4 de la leukotriene
JP2003521894A (ja) 新規のヒトｇ−タンパク質共役型受容体
AU2002341602A1 (en) Human schizophrenia gene
EP1578908A2 (fr) Gene humain de la schizophrenie
JP2002345491A (ja) 新規ｇタンパク質共役型レセプタータンパク質およびそのｄｎａ
WO2003002741A2 (fr) Acides nucleiques codant pour des recepteurs nucleaires
US20020165144A1 (en) Human schizophrenia gene
WO2003040393A2 (fr) Acides nucleiques codant des proteases
WO2003002606A2 (fr) Acides nucleiques codant des canaux ioniques
WO2004065938A2 (fr) Gene humain de l'osteoporose
JP2006515992A (ja) ヒト骨粗鬆症遺伝子
WO2003040392A2 (fr) Acides nucleiques codant des enzymes d'une biosynthese d'acide gras a tres longue chaine
WO2004061106A1 (fr) Nouvelle proteine d'origine mammifere regulant negativement l'expression de la molecule associee a la presentation d'antigene telle que la molecule b7-2 ou mhc de classe ii sur la surface des cellules et utilisation correspondante
JP2002355061A (ja) 新規ｇ蛋白質共役型レセプター蛋白質およびそのｄｎａ
JP2001149072A (ja) 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
JP2002345470A (ja) 新規ｇ蛋白質共役型レセプター蛋白質およびそのｄｎａ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP